These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 618580)

  • 21. Corynebacterium parvum as a therapeutic antitumor agent in mice. II. Local injection.
    Scott MT
    J Natl Cancer Inst; 1974 Sep; 53(3):861-5. PubMed ID: 4213016
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of BCG and C. parvum treatment on human melanoma xenografts.
    Garrett AJ; Reeson DE; Osborn TW; Boulger LR
    Dev Biol Stand; 1977 Apr 13-15; 38():363-8. PubMed ID: 608525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contrasting effects of activated and nonactivated macrophages and macrophages from tumor-bearing mice on tumor growth in vivo.
    Gabizon A; Leibovich SJ; Goldman R
    J Natl Cancer Inst; 1980 Nov; 65(5):913-20. PubMed ID: 6933261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activity of Corynebacterium parvum and retinyl palmitate used in combination on the Lewis lung carcinoma.
    Pavelic ZP; Dave S; Bialkowski S; Priore RL; Greco WR
    Cancer Res; 1980 Dec; 40(12):4617-21. PubMed ID: 7438095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Corynebacterium parvum as a therapeutic antitumor agent in mice. I. Systemic effects from intravenous injection.
    Scott MT
    J Natl Cancer Inst; 1974 Sep; 53(3):855-60. PubMed ID: 4213015
    [No Abstract]   [Full Text] [Related]  

  • 26. [The effects of surgical intervention and removal of the primary tumor, and the effectiveness of Corynebacterium parvum on metastatic tumor proliferation].
    Hashimoto O
    Nihon Geka Gakkai Zasshi; 1983 Jul; 84(7):577-90. PubMed ID: 6676630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Corynebacterium parvum and chronic Toxoplasma infection on metastatic brain tumors in mice.
    Conley FK
    J Natl Cancer Inst; 1979 Nov; 63(5):1237-44. PubMed ID: 291750
    [No Abstract]   [Full Text] [Related]  

  • 28. Responsiveness of senescent mice to the antitumor properties of Corynebacterium parvum.
    Yuhas JM; Ullrich RL
    Cancer Res; 1976 Jan; 36(1):161-6. PubMed ID: 1247995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the inhibition of tumor growth following local or systemic administration of Corynebacterium parvum or other immunostimulating agents with or without cyclophosphamide.
    Fisher B; Gebhardt M; Linta J; Saffer E
    Cancer Res; 1978 Sep; 38(9):2679-87. PubMed ID: 679170
    [No Abstract]   [Full Text] [Related]  

  • 30. Corynebacterium parvum and cyclophosphamide as combination treatment for a murine mammary adenocarcinoma.
    Purnell DM; Bartlett GL; Kreider JW; Biro TG
    Cancer Res; 1977 Apr; 37(4):1137-40. PubMed ID: 844041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proceedings: Combined surgery and Corynebacterium parvum for treatment of metastasizing tumour in mice.
    Castro JE; Sadler TE
    Br J Surg; 1975 Feb; 62(2):156. PubMed ID: 1115892
    [No Abstract]   [Full Text] [Related]  

  • 32. Dose, route, and time dependence of serum lysozyme and antitumor activity following administration of glucan, Corynebacterium parvum, pyran, or lipopolysaccharide to mice.
    Gorecka-Tisera A; Proctor JW; Yamamura Y; Harnaha J; Meinert K
    J Natl Cancer Inst; 1981 Oct; 67(4):911-5. PubMed ID: 6944557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in syngeneic tumor-bearing mice.
    Wolmark N; Fisher B
    Cancer Res; 1974 Nov; 34(11):2869-72. PubMed ID: 4419513
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunotherapy of an established rat mammary adenocarcinoma (13762A) with intratumor injection of Corynebacterium parvum.
    Kreider JW; Bartlett GL; Purnell DM; Webb S
    Cancer Res; 1978 Mar; 38(3):689-92. PubMed ID: 626972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Failure of Corynebacterium parvum presensitization to modify the antitumor effects of systemic and local therapeutic injections of C. parvum in mice.
    Scott MT
    J Natl Cancer Inst; 1976 Mar; 56(3):675-7. PubMed ID: 815560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An experimental screening for "systemic adjuvants of immunity" applicable in cancer immunotherapy.
    Mathé G; Kamel M; Dezfulian M; Halle-Pannenko O; Bourut C
    Cancer Res; 1973 Sep; 33(9):1987-97. PubMed ID: 4146853
    [No Abstract]   [Full Text] [Related]  

  • 37. Proceedings: Therapy of methyl cholanthrene induced CBA mouse tumours with Corynebacterium parvum and irradiated tumour cells.
    Bomford R
    Br J Cancer; 1975 Aug; 32(2):241. PubMed ID: 1212356
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunotherapy of cancer with corynebacterium parvum.
    Halpern B
    Ann Allergy; 1978 Mar; 40(3):155-7. PubMed ID: 637374
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of vaccine prepared from Corynebacterium parvum on the growth of Gardner lymphosarcoma in C3H strain mice.
    Motycka K; Chudomel V; Bednár M; Bostík J
    Arch Immunol Ther Exp (Warsz); 1984; 32(4):405-12. PubMed ID: 6549499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accessory cell function in tumor-bearing mice and effects of Corynebacterium parvum.
    Okuda S; Taniguchi K; Kubo C; Nomoto K
    J Natl Cancer Inst; 1982 Dec; 69(6):1293-7. PubMed ID: 6292563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.